SiNtx Technologies Inc (SINT)

[boston745]

My belief in the product and the constant assault the stock has been under has gotten me to this point.

There is no conceivable reason for the market-cap other than funds can make money shorting it while things develop.


I've ran out of posts for the day but what changed my perception was the Weigao deal followed by more research into the product.

This for instance:

In the 1970s, several studies revealed the requirement for silicon in bone development, whilst bioactive silicate glasses simultaneously pioneered the current era of bioactive materials. Considerable research has subsequently focused on the chemistry and biological function of silicon in bone, demonstrating that the element has at least two separate effects in the extracellular matrix: i) interacting with glycosaminoglycans and proteoglycans during their synthesis, and ii) forming ionic substitutions in the crystal lattice structure of hydroxyapatite. In addition, the dissolution products of bioactive glass (predominantly silicic acids) have significant effects on the molecular biology of osteoblasts in vitro, regulating the expression of several genes including key osteoblastic markers, cell cycle regulators and extracellular matrix proteins. Researchers have sought to capitalise on these effects and have generated a diverse array of biomaterials which include bioactive glasses, silicon-substituted hydroxyapatites and pure, porosified silicon, but all these materials share similarities in the mechanisms that result in their bioactivity. In this review we discuss the current data obtained from original research in biochemistry and biomaterials science supporting the role of silicon in bone, comparing both the biological function of the element and analysing the evolution of silicon-containing biomaterials.

Silicon: The evolution of its use in biomaterials. Available from: https://www.researchgate.net/publication/266029027_Silicon_The_evolution_of_its_use_in_biomaterials [accessed Nov 15 2017].